{"id":"W2984221112","doi":"10.1016/j.jhep.2019.11.003","title":"Guidance for design and endpoints of clinical trials in chronic hepatitis B - Report from the 2019 EASL-AASLD HBV Treatment Endpoints Conference‡","year":2019,"lang":"en","type":"review","venue":"Journal of Hepatology","topic":"Hepatitis B Virus Studies","field":"Medicine","cited_by":358,"is_retracted":false,"has_abstract":false,"ca_institutions":"","funders":"Barts and The London School of Medicine and Dentistry; Perelman School of Medicine, University of Pennsylvania; Universitätsklinikum Hamburg-Eppendorf; National Institutes of Health; European Association for the Study of the Liver; National and Kapodistrian University of Athens; Università degli Studi di Parma; University of Toronto; University College London; National Institute for Health and Care Research; Universitätsklinikum Essen; Università degli Studi di Milano; University of Pennsylvania; Barts Charity; Universität Duisburg-Essen; Roche; Gilead Sciences; Deutsches Zentrum für Infektionsforschung; Universität Hamburg; Bristol-Myers Squibb","keywords":"Medicine; HBsAg; Clinical endpoint; Clinical trial; Internal medicine; Surrogate endpoint; Hepatitis B; Discontinuation; HBeAg; Chronic hepatitis; cccDNA; Hepatitis B virus; Gastroenterology; Immunology; Virus","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.5009424665261447,"score_gpt":0.5366977400755869,"score_spread":0.03575527354944219,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}